English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NA /

TL-895-203

An Open-Label, Multicenter, Phase 1b/2 Study Of The Safety And Efficacy Of TL-895 Combined With KRT-232 In Subjects With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)

DISEASE GROUP:
Leukemia
current phase:
Phase I/II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: